Continuous Azithromycin in Cystic Fibrosis Patients Beyond Two Years (AZITHRO)

Civil Hospices of Lyon

Status: Completed

Conditions: Cystic Fibrosis

Treatments: Drug: Azithromycin

Study type: Observational

Funder types: Other

Identifiers

NCT02803944

69HCL14_0240

Details and patient eligibility

About

Azithromycin is an antibiotic currently prescribed continuously in cystic fibrosis patients. It was shown that this treatment taken every day or every week for 12 months, can improve the respiratory state of patients. From the second year of treatment, it would appear there is more profit to continue such treatment.

The main objective is to study the association between continuous use of azithromycin and lung function measured by Forced expiratory volume in one second (FEV1), after two years of treatment.

Enrollment: 2,055 patients

Sex: All

Ages: 7+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with Cystic Fibrosis (whatever the genetic form)
• Age ≥ 8 years
• FEV ≥ 30% the year of azithromycin (N0)
• Continuous treatment with azithromycin for at least 2 years.

Exclusion criteria

Trial design

2,055 participants in 1 patient group

Cystic fibrosis patients taking azithromycin

Description:

Cystic fibrosis patients taking azithromycin continuously for two years.

Treatment:

Drug: Azithromycin